| Name | Title | Contact Details |
|---|
54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.
The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yields during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme`s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company`s partners make progress developing and commercializing their products being developed using ENHANZE®
Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.